Repetitive shock therapy of subcutaneous implantable cardioverter defibrillators in a patient with idiopathic ventricular fibrillation: What is the mechanism?

J Cardiovasc Electrophysiol. 2019 Oct;30(10):2121-2124. doi: 10.1111/jce.14078. Epub 2019 Jul 28.

Authors

Kanae Hasegawa¹, Shinsuke Miyazaki¹, Eri Ishikawa¹, Moe Mukai¹, Daisetsu Aoyama¹, Minoru Nodera¹, Kenichi Kaseno¹, Hiroshi Tada¹

Affiliation

¹ Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

PMID: 31332856
DOI: 10.1111/jce.14078

No abstract available

Keywords: shock; subcutaneous implantable cardioverter defibrillator; ventricular fibrillation.

Publication types

Case Reports

MeSH terms

Ablation Techniques*
Action Potentials
Anti-Arrhythmia Agents / administration & dosage
Cilostazol / administration & dosage
Defibrillators, Implantable*
Electric Countershock / adverse effects
Electric Countershock / instrumentation*
Electrocardiography
Electrophysiologic Techniques, Cardiac
Heart Rate
Humans
Male
Middle Aged
Prosthesis Failure
Purkinje Fibers / drug effects
Purkinje Fibers / physiopathology
Purkinje Fibers / surgery*
Tachycardia, Ventricular / diagnosis
Tachycardia, Ventricular / physiopathology
Tachycardia, Ventricular / surgery*
Time Factors
Treatment Outcome
Ventricular Fibrillation / diagnosis
Ventricular Fibrillation / physiopathology
Ventricular Fibrillation / therapy*
Verapamil

Substances

Anti-Arrhythmia Agents
Verapamil
Cilostazol

Supplementary concepts

Paroxysmal ventricular fibrillation